The global hemato oncology testing market size was estimated at USD 3.60 billion in 2024 and is projected to reach USD 7.44 billion by 2030, growing at a CAGR of 12.99% from 2025 to 2030. Hemato-oncology pertains to the diagnosis, treatment, and prevention of blood-related cancers and hematologic disorders, including conditions such as leukemia, lymphoma, and myeloma.

Several key factors are expected to drive the expansion of this market over the coming years. These include the rising incidence of blood cancers like lymphoma and myeloma, an increasing shift toward personalized therapies, the advancement and accessibility of sophisticated molecular diagnostic technologies, and the growing emphasis on drug-diagnostic co-development to support targeted treatment strategies. Together, these trends are accelerating the adoption of advanced testing methods in clinical settings.

One of the most transformative developments in the field is the rapid evolution of molecular diagnostics, which has revolutionized how hematologic malignancies are detected, characterized, and treated. These modern diagnostic tools now enable clinicians to adopt highly precise, patient-tailored approaches that improve the accuracy of diagnoses, predict disease progression more effectively, and guide therapeutic decisions. This not only enhances patient outcomes but also contributes to streamlined and efficient clinical workflows.

Molecular diagnostics in hematologic cancers frequently utilize technologies such as real-time polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS) to identify critical genetic mutations and alterations. For example, chronic myeloid leukemia (CML) is typically diagnosed using PCR assays that detect the BCR::ABL1 fusion gene, or with FISH techniques that visualize chromosomal changes. Moreover, the global standardization of BCR/ABL quantification has enabled more consistent and reliable diagnostic practices across laboratories worldwide.

In the case of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), NGS panels are widely applied to detect multiple mutations in genes such as FLT3-ITD, NPM1, and TP53, which are essential for determining patient prognosis and selecting appropriate treatment options. For lymphomas, a variety of molecular tools—such as T-cell receptor clonality assays, targeted FISH, and immunoglobulin heavy chain (IgVH) analysis—are employed to support diagnosis and disease classification. Furthermore, the JAK2 V617F mutation plays a pivotal role in diagnosing polycythemia vera, especially in patients considered to be at high risk.

Key Market Trends & Insights:

• In 2024, the North American hemato-oncology testing market accounted for the largest share, representing 40.40% of the global market. This dominant position is largely attributed to the region’s advanced healthcare infrastructure, high adoption of molecular diagnostic technologies, and significant investments in cancer research and development. Additionally, strong presence of key market players and widespread awareness regarding early cancer detection further contribute to the market leadership of North America in this sector.

• Within North America, the United States remains a major contributor and is anticipated to experience moderate growth in its hemato-oncology testing market throughout the forecast period. This steady expansion is driven by ongoing advancements in diagnostic techniques, increasing prevalence of hematologic malignancies, and supportive government initiatives aimed at enhancing cancer diagnostics and treatment.

• When analyzed by cancer type, the lymphoma segment emerged as the most prominent in 2024, capturing the largest market share of 47.04%. This can be attributed to the high incidence rates of various forms of lymphoma, including Hodgkin and non-Hodgkin types, along with the increasing use of targeted diagnostic tests for early and accurate detection.

• From a product perspective, the services segment held the largest market share in 2024. The dominance of this segment is primarily driven by the growing reliance on specialized diagnostic services offered by laboratories, hospitals, and diagnostic centers, which include genetic testing, biomarker analysis, and personalized profiling essential for precise treatment planning in hemato-oncology.

• In terms of end use, the hospitals segment accounted for the largest market share in 2024. Hospitals serve as the primary centers for cancer diagnosis and treatment, offering a comprehensive range of testing services supported by advanced laboratory infrastructure and skilled medical personnel. The increasing integration of molecular diagnostics within hospital settings has further strengthened this segment’s position in the market.

Order a free sample PDF of the Hemato Oncology Testing Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 3.60 Billion

• 2030 Projected Market Size: USD 7.44 Billion

• CAGR (2025-2030): 12.99%

• North America: Largest market in 2024

Key Companies & Market Share Insights:

Major players in the hemato-oncology testing market actively pursue a variety of strategic initiatives to strengthen their market presence and competitiveness. These strategies commonly include distribution agreements, which enable companies to expand their geographical reach and improve access to their products through local or regional partners. Additionally, mergers and acquisitions are frequently employed to consolidate market position, gain access to new technologies, and diversify product portfolios by integrating complementary capabilities.

Market expansion efforts are also a key focus, with companies investing in the development of new facilities, laboratories, or operational hubs to support growing demand and better serve target markets. However, among all these strategic approaches, the most critical and impactful is the emphasis on continuous innovation in product research and development (R&D). By investing heavily in R&D, these companies aim to develop advanced diagnostic technologies, improve test accuracy and speed, and introduce next-generation solutions tailored to the evolving needs of hemato-oncology.

This strong focus on innovation not only enhances the clinical effectiveness of their offerings but also allows these players to differentiate themselves in a competitive landscape and achieve deeper market penetration. Ultimately, these combined efforts help drive sustained growth and ensure leadership in the dynamic and rapidly advancing field of hemato-oncology diagnostics.

Key Players

• F. Hoffmann-La Roche Ltd

• Abbott

• EntroGen, Inc.

• Qiagen N.V.

• Cepheid (Danaher Corporation)

• Thermo Fisher Scientific, Inc.

• Bio-Rad Laboratories, Inc.

• Illumina, Inc.

• Amoy Diagnostics Co., Ltd.

• ASURAGEN, INC

• ArcherDX, Inc. (IDT)

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The hemato-oncology testing market is undergoing robust expansion driven by rising cases of blood-related cancers like lymphoma and myeloma, and the steady progression toward personalized medicine. Technological advancements—especially in molecular diagnostics such as NGS, PCR, and liquid biopsy—are enhancing early detection and treatment planning. Strategic collaborations between diagnostic firms, research institutions, and pharmaceutical companies are fostering the development of next-generation tests and companion diagnostics. Despite regional disparities in diagnostic adoption and regulatory complexities, ongoing innovation and supportive healthcare initiatives position the market for sustained growth and deeper clinical integration.